You are here

Jun 28, 2011

The Catalan biotech enterprise Iproteos, promoted by IRB Barcelona and the University of Barcelona, will apply new strategies to discover drugs with greater efficiency and fewer side effects. Iproteos, founded by Dr. Teresa Tarragó, researcher at Institute for Research in Biomedicine (IRB Barcelona) and Prof. Ernest Giralt, coordinator of the Chemistry and Molecular Pharmacology Programme at IRB Barcelona and senior professor of the University of Barcelona will search for peptides that block the activity of proteases, key therapeutic targets for the treatment of a wide range of diseases.